|
| |
EGFR
| Symbol: | EGFR | | Name(s): | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | | Type: | protein-coding | | Organism: | Homo sapiens | | Synonyms: | ERBB, ERBB1, HER1, PIG61, mENA | | Links: |
Pubmed,
Entrez Gene,
GeneCards,
BioGPS,
Map Viewer.
|
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18172732 |
EGFR overexpression was found in 87.5% (35/40) of the laryngeal primary tumors and 82.5% (33/40) of the corresponding lymph node metastases. There was a good agreement between the primary tumors and the paired metastases regarding EGFR expression. |
| 17912028 |
This study aimed to explore, whether polymorphisms in BCL2, Cyclin D1, FAS, EGF and EGFR genes affect survival in a cohort of patients with squamous cell esophageal cancer treated with CT+RT with a view to identify the potential therapeutic targets. |
| 18045238 |
amphiregulin-specific EGF-R fate results from decreased hSprouty2 degradation and reduced Cbl recruitment to underphosphorylated EGF-R, two effects that impair EGF-R trafficking to lysosomes |
| 18211286 |
examination of role of lipids in HER1/HER2-driven progression of human breast epithelial cells towards malignancy |
| 18161656 |
AC dinucleotide repeat polymorphism in intron 1 of human EGFR may have a role in breast cancer in certain ethnic groups |
| 18182111 |
Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian cancer. |
| 18334834 |
siRNA-mediated knockdown is effective in lung adenocarcinomas with EGFR mutation and those with resistance to gefitinib by acquired mutation in EGFR. |
| 18084281 |
Results indicate that GEP100 links EGFR signalling to Arf6 activation to induce invasive activities of some breast cancer cells, and hence may contribute to their metastasis and malignancy. |
| 18202784 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 18261621 |
Observational study of gene-disease association. (HuGE Navigator) | →View more information from publications. |
Recent Publications on EGFR: |  |
The Egfr-Sox2-Egfr Feed-Back Loop Positively Regulates the Self-Renewal of Neural Precursor Cells.
The transcriptional factor Sox2 and epidermal growth factor receptor... | 3rd November, 2009
| Peking University Stem Cell Research Center and National Center for
| Stem Cells. 2009 Oct 30.
DOI Direct Link |
The EGFR Pathway as an Example for Genotype: Phenotype Correlation in Tumor Genes.
Tumor-specific and germ-line variations of DNA significantly contribute to... | 3rd November, 2009
| Department of Internal Medicine I, University Hospital Carl Gustav Carus,
| Methods Mol Biol. 2010;576:341-50.
DOI Direct Link |
The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.
The epithelial-to-mesenchymal transition (EMT) that occurs during... | 3rd November, 2009
| Department of Pharmaceutical Sciences, College of Pharmacy, University of
| Neoplasia. 2009 Nov;11(11):1208-15.
|
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Chemotherapy for metastatic bladder cancer is rarely curative. The... | 3rd November, 2009
| Department of Molecular Physiology and Biological Physics, University of
| Neoplasia. 2009 Nov;11(11):1185-93.
|
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
Notch signaling is a highly conserved pathway important for normal... | 3rd November, 2009
| Division of Hematology and Medical Oncology, Vanderbilt University Medical
| Oncogene. 2009 Nov 2.
DOI Direct Link |
→View more research publications. |
Press Releases on EGFR:
|
 |
| Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer |
5th November, 2009 |
Amgen |
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab)
|
| YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 |
2nd November, 2009 |
YM BioSciences Inc. |
- Follow-On Results from a Randomized Phase IIb Head & Neck Trial
Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated
Toxicities -
MISSISSAUGA,
|
| YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG |
29th October, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| Reportlinker Adds Approaches to Reducing Phase II Attrition |
26th October, 2009 |
Reportlinker |
-- Survey results and expert interviews on efforts to improve R&D
efficiency.
Pharmaceutical companies have been responding to a combination of major challenges that
|
| Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody |
1st October, 2009 |
Merrimack Pharmaceuticals, Inc. |
CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the
|
EGFR results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for EGFR,
or search for EGFR on BioPortfolio's antibody search engine.
This page has been viewed 841 times
Recent Search Terms used to find this page: antibody siRNA targeting internalization leukemia | egfr cancer | receptor oncogene | Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog avian) (EGFR) | EGF erythroblast | avian epidermal growth factor | Rab22B is expressed in the CNS astroglia lineage and plays a role in epidermal growth factor receptor trafficking in A431 cells. | diagnostic innovation epidermal | egfr avian | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
